CS-8958 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Trial Profile

CS-8958 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Aviragen Therapeutics; Biota Holdings
  • Most Recent Events

    • 11 Jan 2009 Status changed from active, no longer recruiting to completed, according to the clinicaltrials.gov record.
    • 17 Dec 2007 Status changed from recruiting to in progress according to ClinicalTrials.gov.
    • 26 Apr 2007 Status changed from initiated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top